Phage nanocarriers for mrna delivery in colorectal cancer therapy
Innovative M13 bacteriophage nanocarriers are designed for precise mRNA delivery in colorectal cancer therapy, targeting carcinoembryonic antigen to enhance specificity and reduce systemic toxicity. This platform aims to improve therapeutic efficacy while minimizing off-target effects.
Overview
The proposed solution involves using engineered M13 bacteriophages as biodegradable nanocarriers for delivering mRNA specifically to colorectal cancer cells. By displaying ligands that target the carcinoembryonic antigen (CEA), these phages provide precise delivery of mRNA, promoting targeted protein production in cancer cells. This method is anticipated to exhibit high specificity and low immunogenicity, offering a scalable alternative to traditional delivery systems and highlighting potential expansion into other cancer treatments.
Technical specifications
Key features:
- Precision targeting: Utilizes M13 bacteriophages engineered to bind specifically to CEA on cancer cells.
- mRNA encapsulation: Capable of encapsulating and delivering mRNA to induce targeted protein expression within cancer cells.
- Reduced toxicity: Minimizes off-target effects and systemic toxicity, enhancing therapeutic safety.
- Scalability: Offers a scalable and low-toxicity alternative to conventional delivery methods, with potential applications beyond colorectal cancer.
Technology readiness level
This technology is currently at TRL 3, indicating experimental proof of concept. The next steps include preclinical validation in cancer cell lines and mouse models to assess tumor reduction and systemic safety, aiming to establish a scalable oncotherapy protocol.
About University of South Australia
Formerly a comprehensive public research university based in Adelaide, UniSA operated multiple city and regional campuses; operations transitioned to the new Adelaide University on January 1, 2026, with an official opening on January 29, 2026. For industry, a one‑stop Enterprise Hub streamlined access to consulting, testing and bespoke training. Co‑located facilities in Adelaide BioMed City (including the UniSA Cancer Research Institute/Bradley Building) enabled close links with hospital partners, while the Mawson Lakes campus adjoined Technology Park to anchor defence and advanced‑technology collaborations. Research was consistently supported by competitive national funding from the Australian Research Council and the National Health and Medical Research Council, often alongside matched industry support. Commercialisation was backed by a dedicated technology transfer function and the Innovation & Collaboration Centre’s incubation and acceleration programs.
delivered to your inbox.